Imagion MRI applications as a new source of revenue
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Imagion Biosystems (ASX:IBX) have increased approximately three-fold since June on the back of significant developments with its early stage cancer detection technologies.
However, they could get a further boost on Monday after the company advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).
Executive chairman Bob Proulx said, “While development of our proprietary magnetic relaxometry technology has been our focus to date, this new preliminary work shows the potential for our MagSenseTM nanoparticles to work with MRI and could open up a new commercial pathway as a contrast agent that can be used to improve the effectiveness of MRI in the detection and monitoring of HER2 breast cancer.”
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
By combining biotechnology and nanotechnology, the company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.
A key development that provided considerable interest in the stock was the designation by the FDA of its MagSense System and Test for staging HER2 breast cancer as a breakthrough device.
The purpose of the Breakthrough Device Program is to expedite and improve communications between a device manufacturer and the agency during device development.
Highlighting the importance of this development, Proulx said, "Qualifying as a Breakthrough Device validates our MagSense technology as a transformative opportunity for healthcare, and could improve the standard of care for staging HER breast cancer."
Potential as an MRI contrast agent
The company is progressing with a study where early stage results have demonstrated that the anti-HER2 nanoparticles used in Imagion’s MagSenseTM technology, which provide specific targeting of cancerous cells, may also have potential as an MR imaging (MRI) contrast agent.
Importantly, the study shows the MagSenseTM nanoparticles may be equally effective as a multi-modal molecular imaging agent, generating detectable signals in two different imaging methods - super magnetic relaxometry (SPMR) and magnetic resonance imaging (MRI).
In the MRI setting, contrast agents are used to enhance the image and improve resolution.
However, to date, imaging agents have been general purpose, creating contrast at tissue boundaries but not providing functional imaging utility.
A targeted MagSenseTM nanoparticle detectable by SPMR, that also could be used as a contrast agent to enhance an MR image of specific tissue would create an opportunity for Imagion to work with the large installed base of existing MRI machines.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.